STOCK TITAN

Abeona Therapeutics® Announces Participation in November Investor Conferences

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Abeona Therapeutics (Nasdaq: ABEO) announced its management team's participation in two upcoming investor conferences in November 2024. The company will attend the Truist Securities BioPharma Symposium for investor meetings on November 7, and the Stifel 2024 Healthcare Conference on November 18, which includes a fireside chat at 4:10 p.m. ET and investor meetings. A live webcast of the fireside chat will be available on Abeona's website investor section, with a replay available for a time.

Abeona Therapeutics (Nasdaq: ABEO) ha annunciato la partecipazione del suo team di gestione a due prossime conferenze per investitori a novembre 2024. L'azienda parteciperà al Truist Securities BioPharma Symposium per incontri con gli investitori il 7 novembre, e al Stifel 2024 Healthcare Conference il 18 novembre, che include una chiacchierata informale alle 16:10 ET e incontri con gli investitori. Una trasmissione in diretta della chiacchierata sarà disponibile nella sezione per investitori del sito web di Abeona, con una registrazione disponibile per un certo periodo.

Abeona Therapeutics (Nasdaq: ABEO) anunció la participación de su equipo de gestión en dos conferencias de inversores que se celebrarán en noviembre de 2024. La compañía asistirá al Simposio BioPharma de Truist Securities para reuniones con inversores el 7 de noviembre, y a la Conferencia de Atención Médica de Stifel 2024 el 18 de noviembre, que incluye una charla informal a las 4:10 p.m. ET y reuniones con inversores. Se podrá acceder a una transmisión en vivo de la charla en el sitio web de Abeona, en la sección para inversores, con una repetición disponible durante un tiempo.

아베오나 테라퓨틱스 (Nasdaq: ABEO)는 2024년 11월에 있을 두 개의 투자자 회의에 경영진이 참여한다고 발표했습니다. 회사는 11월 7일 트루이스트 증권 생명공학 심포지엄에 참석하여 투자자 회의를 진행하며, 11월 18일에는 스티펠 2024 헬스케어 컨퍼런스에 참석하여 오후 4시 10분 ET에 열리는 화상 대화 및 투자자 회의가 포함되어 있습니다. 화상 대화의 실시간 웹캐스트는 아베오나의 웹사이트 투자자 섹션에서 제공되며, 특정 기간 동안 재생할 수 있습니다.

Abeona Therapeutics (Nasdaq: ABEO) a annoncé la participation de son équipe de direction à deux conférences d'investisseurs prévues en novembre 2024. L'entreprise assistera au Symposium BioPharma de Truist Securities pour des réunions avec des investisseurs le 7 novembre, et à la Conférence Santé 2024 de Stifel le 18 novembre, qui inclut un chat informel à 16h10 ET et des réunions avec des investisseurs. Une diffusion en direct du chat sera disponible sur la section investisseurs du site Web d'Abeona, avec un replay disponible pendant un certain temps.

Abeona Therapeutics (Nasdaq: ABEO) gab die Teilnahme seines Management-Teams an zwei bevorstehenden Investorenkonferenzen im November 2024 bekannt. Das Unternehmen wird am 7. November am Truist Securities BioPharma Symposium teilnehmen und am 18. November an der Stifel 2024 Healthcare Conference, die ein Fireside-Chat um 16:10 Uhr ET und Investorengespräche umfasst. Ein Live-Stream des Fireside-Chats wird auf der Investoren-Seite von Abeona's Website verfügbar sein, mit einer Wiederholung für eine gewisse Zeit.

Positive
  • None.
Negative
  • None.

CLEVELAND, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2024:

  • Truist Securities BioPharma Symposium: Investor meetings on Thursday, November 7, 2024.
  • Stifel 2024 Healthcare Conference: Fireside chat on Monday, November 18, 2024 at 4:10 p.m. ET and investor meetings.

A live webcast of the fireside chat can be accessed on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events, where a replay of the events will also be available for a limited time.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of the FDA’s review of our BLA resubmission for pz-cel; the FDA’s grant of a Priority Review Voucher upon pz-cel approval; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.


FAQ

When is Abeona Therapeutics (ABEO) participating in the Truist Securities BioPharma Symposium?

Abeona Therapeutics will participate in investor meetings at the Truist Securities BioPharma Symposium on Thursday, November 7, 2024.

What time is Abeona Therapeutics' (ABEO) fireside chat at the Stifel 2024 Healthcare Conference?

Abeona Therapeutics' fireside chat at the Stifel 2024 Healthcare Conference is scheduled for Monday, November 18, 2024, at 4:10 p.m. ET.

Where can investors watch Abeona Therapeutics' (ABEO) fireside chat presentation?

Investors can watch the live webcast of the fireside chat on the Investors section of Abeona's website under 'Events' at investors.abeonatherapeutics.com/events, where a replay will also be available for a time.

Abeona Therapeutics Inc.

NASDAQ:ABEO

ABEO Rankings

ABEO Latest News

ABEO Stock Data

261.62M
43.31M
5.06%
79.3%
6.39%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CLEVELAND